Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 15 Results

Title
Intervention Indication Therapeutic Area Year Actions
Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2019 View  |  Download
Nivolumab with ipilimumab adjuvant therapy for renal cell carcinoma Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Pembrolizumab for renal cell carcinoma - adjuvant therapy post nephrectomy Pembrolizumab (Keytruda; MK-3475) Renal cell carcinoma (RCC) Renal Cancer 2020 View  |  Download
Pembrolizumab in combination with Axitinib for Metastatic Renal Cell Carcinoma – first line Axitinib (Inlyta; AG-013736) , Pembrolizumab (Keytruda; MK-3475) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Savolitinib for MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma Savolitinib (AZD6094) Renal cell carcinoma (RCC) Renal Cancer 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications